{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T06:17:11Z","timestamp":1738131431301,"version":"3.33.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2008,3,13]],"date-time":"2008-03-13T00:00:00Z","timestamp":1205366400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1007\/s00108-008-2017-z","type":"journal-article","created":{"date-parts":[[2008,3,11]],"date-time":"2008-03-11T10:30:30Z","timestamp":1205231430000},"page":"628-634","source":"Crossref","is-referenced-by-count":2,"title":["Pharmakologie und klinische Bedeutung von Vasopressinantagonisten","Pharmacology and clinical relevance of vasopressin antagonists"],"prefix":"10.1007","volume":"49","author":[{"given":"R.","family":"Lemmens-Gruber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kamyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,3,13]]},"reference":[{"key":"2017_CR1","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1210\/me.2004-0080","volume":"18","author":"Bernier","year":"2004","unstructured":"Bernier V, Lagace M, Lonergan M et al. (2004) Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059. Mol Endocrinol 18: 2074\u20132084","journal-title":"Mol Endocrinol"},{"key":"2017_CR2","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1471-0528.2000.tb13302.x","volume":"107","author":"Brouard","year":"2000","unstructured":"Brouard R, Bossmar T, Fournie-Lloret D et al. (2000) Effect of SR49059, an orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea. BJOG 107: 614\u2013619","journal-title":"BJOG"},{"key":"2017_CR3","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s002280050685","volume":"55","author":"Burnier","year":"1999","unstructured":"Burnier M, Fricker AF, Hayoz D et al. (1999) Pharmakokinetic and pharmacodynamic effects of YM087, a combined V1\/V2 vasopressin receptor antagonist in normal subjects. Eur J Clin Pharmacol 55: 633\u2013637","journal-title":"Eur J Clin Pharmacol"},{"key":"2017_CR4","doi-asserted-by":"crossref","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","volume":"290","author":"Costello-Boerrigter","year":"2006","unstructured":"Costello-Boerrigter LC, Smith WB, Boerrigter G et al. (2006) Vasopressin-2-receptor antagonism augments water excretion without changes in renal haemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 290: F273\u2013F278","journal-title":"Am J Physiol Renal Physiol"},{"key":"2017_CR5","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9343(01)00678-7","volume":"110","author":"Decaux","year":"2001","unstructured":"Decaux G (2001) Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am J Med 110: 582\u2013584","journal-title":"Am J Med"},{"key":"2017_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/CS20030062","volume":"Sci","author":"Ferguson","year":"2003","unstructured":"Ferguson JW, Therapondos G, Newby DE, Hayes PC (2003) Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis. Clin Sci (Lond) 105: 1\u20138","journal-title":"Clin"},{"key":"2017_CR7","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0168-8278(03)00116-8","volume":"38","author":"Fernandez-Varo","year":"2003","unstructured":"Fernandez-Varo G, Ros J, Cejudo-Martin P et al. (2003) Effect of the V1\/V2-AVP receptor antagonist, conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites. J Hepatol 38: 755\u2013761","journal-title":"J Hepatol"},{"key":"2017_CR8","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1053\/gast.2003.50143","volume":"124","author":"Gerbes","year":"2003","unstructured":"Gerbes AL, Gulberg V, Gines P et al.; VPA Study Group (2003) Therapy of hyponatremia in cirrhosis with vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 124: 933\u2013939","journal-title":"Gastroenterology"},{"key":"2017_CR9","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1210\/jc.2005-2287","volume":"91","author":"Ghali","year":"2006","unstructured":"Ghali JK, Koren MJ, Taylor JR et al.; Conivaptan Study Group (2006) Efficacy and safety of oral conivaptan: A V1A\/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 91: 2145\u20132152","journal-title":"J Clin Endocrinol Metab"},{"key":"2017_CR10","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","volume":"107","author":"Gheorghiade","year":"2003","unstructured":"Gheorghiade M, Niazi I, Ouyang J et al.; Tolvaptan Investigators (2003) Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 107: 2690\u20132696","journal-title":"Circulation"},{"key":"2017_CR11","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","volume":"291","author":"Gheorghiade","year":"2004","unstructured":"Gheorghiade M, Gattis WA, O\u2019Connor CM et al.; The Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators (2004) Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291: 1963\u20131971","journal-title":"JAMA"},{"key":"2017_CR12","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1073\/pnas.092012099","volume":"99","author":"Griebel","year":"2002","unstructured":"Griebel G, Simiand J, Serradeil-Le Gal C et al. (2002) Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci U S A 99: 6370\u20136375","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2017_CR13","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1053\/jhep.2002.36375","volume":"36","author":"Guyader","year":"2002","unstructured":"Guyader D, Patat A, Ellis-Grosse EJ, Orczyk GP (2002) Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 36: 1197\u20131205","journal-title":"Hepatology"},{"key":"2017_CR14","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/rheumatology\/39.10.1132","volume":"39","author":"Hayoz","year":"2000","unstructured":"Hayoz D, Bizzinin G, Noel B et al. (2000) Effect of SR49059, a V1a vasopressin receptor antagonist, in Raynaud\u2019s phenomenon. Rheumatology 39: 1132\u20131138","journal-title":"Rheumatology"},{"key":"2017_CR15","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","volume":"297","author":"Konstam","year":"2007","unstructured":"Konstam MA, Gheorghiade M, Burnett JC et al.; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators (2007) Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297: 1319\u20131331","journal-title":"JAMA"},{"key":"2017_CR16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1089\/jop.2000.16.203","volume":"16","author":"Lacheretz","year":"2000","unstructured":"Lacheretz F, Barbier A, Serradeil-Le Gal C et al. (2000) Effect of SSR121463, a selective non-peptide vasopressin V2 receptor antagonist, in a rabbit model of ocular hypertension. J Ocul Pharmacol Ther 16: 203\u2013216","journal-title":"J Ocul Pharmacol Ther"},{"key":"2017_CR17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pbb.2005.07.021","volume":"82","author":"Overstreet","year":"2005","unstructured":"Overstreet DH, Griebel G (2005) Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat. Pharmacol Biochem Behav 82: 223\u2013227","journal-title":"Pharmacol Biochem Behav"},{"key":"2017_CR18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/17482940701210179","volume":"9","author":"Rossi","year":"2007","unstructured":"Rossi J, Bayram M, Udelson JE et al. (2007) Improvement of hyponatremia during hospitalisation for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card Care 9: 82\u201386","journal-title":"Acute Card Care"},{"key":"2017_CR19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1067\/mhj.2003.39","volume":"145","author":"Russell","year":"2003","unstructured":"Russell S, Selaru P, Pyne DA et al. (2003) Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin Antagonist in CHF patients undergoing Exercise) trial. Am Heart J 145: 179\u2013186","journal-title":"Am Heart J"},{"key":"2017_CR20","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","volume":"355","author":"Schrier","year":"2006","unstructured":"Schrier RW, Gross P, Gheorghiade M et al.; SALT Investigators (2006) Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355: 2099\u20132112","journal-title":"N Engl J Med"},{"key":"2017_CR21","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.2215\/CJN.00160106","volume":"1","author":"Soupart","year":"2006","unstructured":"Soupart A, Gross P, Legros JJ et al. (2006) Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol 1: 1154\u20131160","journal-title":"Clin J Am Soc Nephrol"},{"key":"2017_CR22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0022-3565(24)36784-9","volume":"282","author":"Tahara","year":"1997","unstructured":"Tahara A, Tomura Y, Wada K et al. (1997) Pharmacological profile of YM087, a novel potent vasopressin V1a and V2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 282: 301\u2013308","journal-title":"J Pharmacol Exp Ther"},{"key":"2017_CR23","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.coph.2003.06.005","volume":"3","author":"Thibonnier","year":"2003","unstructured":"Thibonnier M (2003) Vasopressin receptor antagonists in heart failure. Curr Opin Pharmacol 3: 683\u2013687","journal-title":"Curr Opin Pharmacol"},{"key":"2017_CR24","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1517\/13543784.7.5.729","volume":"7","author":"Thibonnier","year":"1998","unstructured":"Thibonnier M (1998) Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists. Expert Opin Investig Drugs 7: 729\u2013740","journal-title":"Expert Opin Investig Drugs"},{"key":"2017_CR25","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.jacc.2007.01.091","volume":"49","author":"Udelson","year":"2007","unstructured":"Udelson JE, McGrew FA, Flores E et al. (2007) Multicenter, randomised, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 49: 2151\u20132159","journal-title":"J Am Coll Cardiol"},{"key":"2017_CR26","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1161\/hc4501.099313","volume":"104","author":"Udelson","year":"2001","unstructured":"Udelson JE, Smith WB, Hendrix GH et al. (2001) Acute hemodynamic effects of conivaptan, a dual V1a and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104: 2417\u20132423","journal-title":"Circulation"},{"key":"2017_CR27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejphar.2004.11.022","volume":"507","author":"Wada","year":"2005","unstructured":"Wada K, Fujimori A, Matsukawa U et al. (2005) Intravenous administration of conivaptan hydrochloride improves cardiac haemodynamics in rats with myocardial infarction-induced congestive heart failure. Eur J Pharmacol 507: 145\u2013151","journal-title":"Eur J Pharmacol"},{"key":"2017_CR28","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1681\/ASN.2005020136","volume":"16","author":"Wang","year":"2005","unstructured":"Wang X, Gattone V 2nd, Harris PC, Torres VE (2005) Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 16: 838\u2013839","journal-title":"J Am Soc Nephrol"},{"key":"2017_CR29","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2003.50021","volume":"37","author":"Wong","year":"2003","unstructured":"Wong F, Blei AT, Blendis LM, Thuluvath PJ (2003) A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 37: 182\u2013191","journal-title":"Hepatology"},{"key":"2017_CR30","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1159\/000106456","volume":"27","author":"Zeltser","year":"2007","unstructured":"Zeltser D, Rosansky S, Rensburg H van et al.; Conivaptan Study Group (2007) Assessment of the efficacy and safety of intravenouzs conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol 27: 447\u2013457","journal-title":"Am J Nephrol"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-008-2017-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-008-2017-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-008-2017-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T01:30:01Z","timestamp":1738114201000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-008-2017-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,13]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["2017"],"URL":"https:\/\/doi.org\/10.1007\/s00108-008-2017-z","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"type":"print","value":"0020-9554"},{"type":"electronic","value":"1432-1289"}],"subject":[],"published":{"date-parts":[[2008,3,13]]}}}